|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...87888990919293949596979899» |
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change, Combination therapy: Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC (clinicaltrials.gov) - Feb 12, 2012
P4, N=610, Completed, Sponsor: Brooke Army Medical Center
N=926 --> 610
- Pegasys (pegylated interferon ? -2a) / Roche
Trial completion: Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba (clinicaltrials.gov) - Feb 12, 2012
P4, N=20, Completed, Sponsor: Brooke Army Medical Center
N=926 --> 610 Enrolling by invitation --> Completed
- | Advaferon (interferon alfacon-1) / Astellas, Sanofi
Trial completion, Combination therapy: Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Feb 12, 2012
P4, N=34, Completed, Sponsor: Brooke Army Medical Center
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion, Combination therapy: Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC (clinicaltrials.gov) - Feb 12, 2012
P4, N=610, Completed, Sponsor: Brooke Army Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- octreotide acetate solution for injection / Generic mfg.
Enrollment change, Metastases: Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer (clinicaltrials.gov) - Feb 11, 2012
P2, N=31, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed N=48 --> 31
- octreotide acetate solution for injection / Generic mfg.
Trial completion, Metastases: Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer (clinicaltrials.gov) - Feb 11, 2012
P2, N=31, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=48 --> 31 Active, not recruiting --> Completed
- |||| CTS-1027 / Histogen
Trial completion, Combination therapy: CTS-1027-04: Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders (clinicaltrials.gov) - Feb 8, 2012
P2, N=67, Completed, Sponsor: Conatus Pharmaceuticals Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| faldaprevir (BI201335) / Boehringer Ingelheim
Enrollment closed, Combination therapy: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3) (clinicaltrials.gov) - Feb 7, 2012
P3, N=678, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| IDX 184 / Merck (MSD)
Enrollment change, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Feb 7, 2012
P2, N=60, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting N=100 --> 60
- Vanihep (vaniprevir) / Merck (MSD)
Enrollment change: Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) (clinicaltrials.gov) - Feb 7, 2012
P1, N=3, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=100 --> 60 N=18 --> 3
- | Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion: Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib (clinicaltrials.gov) - Feb 7, 2012
P1, N=35, Completed, Sponsor: Boehringer Ingelheim
N=18 --> 3 Recruiting --> Completed
- Trial completion, MRI: MRsteatosis: Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications (clinicaltrials.gov) - Feb 6, 2012
P=N/A, N=84, Completed, Sponsor: University of Zurich
Recruiting --> Completed Enrolling by invitation --> Completed
- faldaprevir (BI201335) / Boehringer Ingelheim, deleobuvir (BI 207127) / Boehringer Ingelheim
New P2 trial, Combination therapy: This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C (clinicaltrials.gov) - Feb 6, 2012
P2, N=25, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- ||| iloperidone / Generic mfg.
New P1 trial: Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers (clinicaltrials.gov) - Feb 6, 2012
P1, N=90, Completed, Sponsor: Novartis Pharmaceuticals
- New P1 trial, Surgery, Metastases: Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases (clinicaltrials.gov) - Feb 6, 2012
P1, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- Trial termination: Viro-steatosis: Impact of Hepatitis C Virus Variability on Steatosis (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=27, Terminated, Sponsor: University Hospital, Tours
Enrolling by invitation --> Completed Recruiting --> Terminated
- Review, Enrollment change: A Retrospective Review of Malignant Liver Tumors (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=228, Completed, Sponsor: University of Oklahoma
Recruiting --> Terminated N=500 --> 228
- Trial completion, Review: A Retrospective Review of Malignant Liver Tumors (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=228, Completed, Sponsor: University of Oklahoma
N=500 --> 228 Active, not recruiting --> Completed
- Biomarker, Enrollment change: IRB 2000-294: UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=200, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed N=4350 --> 200
- Biomarker, Trial completion: IRB 2000-294: UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=200, Completed, Sponsor: University of Michigan Cancer Center
N=4350 --> 200 Active, not recruiting --> Completed
- |||| filibuvir (PF-00868554) / Pfizer
Trial completion: Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects (clinicaltrials.gov) - Feb 2, 2012
P2, N=288, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
Trial withdrawal, Combination therapy: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C (clinicaltrials.gov) - Feb 1, 2012
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Not yet recruiting --> Withdrawn
- peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
Enrollment change, Combination therapy: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C (clinicaltrials.gov) - Feb 1, 2012
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=900 --> 0
- ||| faldaprevir (BI201335) / Boehringer Ingelheim, deleobuvir (BI 207127) / Boehringer Ingelheim
New P1 trial, Combination therapy: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients (clinicaltrials.gov) - Feb 1, 2012
P1, N=72, Active, not recruiting, Sponsor: Boehringer Ingelheim
- Enrollment closed: Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: Stanford University
N=900 --> 0 Recruiting --> Active, not recruiting
- |||| Tarvacin (bavituximab) / OncXerna Therap
Trial completion: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection (clinicaltrials.gov) - Feb 1, 2012
P2, N=66, Completed, Sponsor: Peregrine Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse Elastography (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=150, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed Recruiting --> Completed
- New P1 trial: Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients (clinicaltrials.gov) - Jan 31, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
- |||| Locteron (interferon alpha-2b CR) / Biolex
Trial completion: 480S: 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) (clinicaltrials.gov) - Jan 31, 2012
P2, N=74, Completed, Sponsor: Biolex Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Locteron (interferon alpha-2b CR) / Biolex
Trial completion: SELECT-2: Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV (clinicaltrials.gov) - Jan 31, 2012
P2b, N=116, Completed, Sponsor: Biolex Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures (clinicaltrials.gov) - Jan 30, 2012
P2, N=136, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Combination therapy, Metastases: Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 30, 2012
P1, N=20, Completed, Sponsor: Samsung Medical Center
Recruiting --> Completed N=15 --> 20
- | New P2 trial: A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer (clinicaltrials.gov) - Jan 30, 2012
P2, N=70, Recruiting, Sponsor: University of Michigan Cancer Center
- ||| furaprevir (TG-2349) / TaiGen
New P1 trial: A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients (clinicaltrials.gov) - Jan 30, 2012
P1, N=120, Recruiting, Sponsor: TaiGen Biotechnology Co., Ltd.
- New P1 trial, Surgery: Prehabilitation in Liver Surgery (clinicaltrials.gov) - Jan 30, 2012
P1, N=37, Completed, Sponsor: Aintree University Hospitals NHS Foundation Trust
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Combination therapy, Metastases: Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 30, 2012
P1, N=20, Completed, Sponsor: Samsung Medical Center
N=15 --> 20 Recruiting --> Completed
- | tenofovir disoproxil fumarate / Generic mfg.
New P4 trial: EMRP36100N: Tenofovir in Chronic Hepatitis B With Mild ALT Elevation (clinicaltrials.gov) - Jan 29, 2012
P4, N=160, Recruiting, Sponsor: E-DA Hospital
- |||| Aramchol (aramchol meglumine) / Galmed
Trial completion: Aramchol003: Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis (clinicaltrials.gov) - Jan 29, 2012
P2, N=60, Completed, Sponsor: Galmed Medical Reserch
Recruiting --> Completed Recruiting --> Completed
- Trial termination: Genetic Analysis of Liver Cancer (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=41, Terminated, Sponsor: Samuel So
Recruiting --> Completed Recruiting --> Terminated; low accrual
- Enrollment change: Genetic Analysis of Liver Cancer (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=41, Terminated, Sponsor: Samuel So
Recruiting --> Terminated; low accrual N=500 --> 41
- Biomarker, New P1 trial: Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) (clinicaltrials.gov) - Jan 29, 2012
P1, N=12, Terminated, Sponsor: Merck
- Enrollment open: Oslo-CoMett: Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=340, Recruiting, Sponsor: Oslo University Hospital
N=500 --> 41 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 (clinicaltrials.gov) - Jan 29, 2012
P1, N=16, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: HEPAR: Radioactive Holmium Microspheres for the Treatment of Liver Metastases (clinicaltrials.gov) - Jan 29, 2012
P1, N=15, Completed, Sponsor: UMC Utrecht
Recruiting --> Completed Recruiting --> Completed
- |||| setrobuvir (AN598) / Roche
Trial completion, Combination therapy: Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection (clinicaltrials.gov) - Jan 29, 2012
P2, N=97, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Jan 28, 2012
P1, N=25, Completed, Sponsor: CSL Behring
Active, not recruiting --> Completed Recruiting --> Completed
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment change: Open-Label, Bridging Study of Telaprevir in Treatment-Na (clinicaltrials.gov) - Jan 26, 2012
P3, N=36, Completed, Sponsor: Janssen-Cilag International NV
Recruiting --> Completed N=30 --> 36
- ||||| Tyzeka (telbivudine) / Novartis
Enrollment change, Monotherapy: Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB (clinicaltrials.gov) - Jan 25, 2012
P3, N=83, Completed, Sponsor: Novartis Pharmaceuticals
N=30 --> 36 N=60 --> 83
- | Tyzeka (telbivudine) / Novartis
New P4 trial: STEN: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (clinicaltrials.gov) - Jan 25, 2012
P4, N=360, Recruiting, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
- ||||||| Tyzeka (telbivudine) / Novartis
Trial completion, Monotherapy: Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB (clinicaltrials.gov) - Jan 25, 2012
P3, N=83, Completed, Sponsor: Novartis Pharmaceuticals
N=60 --> 83 Recruiting --> Completed